Used in Lieu of PTO/SB/08A/B
(Based on PTO 12-07 version)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 7

Complete if Known	
Application Number	10/566,409-Conf. #3616
Filing Date	August 24, 2006
First Named Inventor	Jeffrey A. Ledbetter
Art Unit	1643
Examiner Name	Not Yet Assigned
Attorney Docket Number	31126/41458P3US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (*if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-2001/0004135	06-21-2001	Okamura	
	A2	US-2002/0031510	03-14-2002	Larsen et al.	
	A3	US-2002/0039557	04-04-2002	White	
	A4	US-2002/0155604	10-24-2002	Ledbetter et al.	
	A5	US-2003/0044423	03-06-2003	Gillies et al.	
	A6	US-2003/0088074	05-08-2003	Hamers et al.	
	A7	US-2003/0133930	07-17-2003	Goldenberg et al.	
	A8	US-2003/0219433	11-27-2003	Hansen et al.	
	A9	US-2003/0219436	11-27-2003	Ledbetter et al.	
	A10	US-2003/0219446	11-27-2003	Linsley et al.	
	A11	US-2003/0219876	11-27-2003	Ledbetter et al.	
	A12	US-2004/0058445	03-25-2004	Ledbetter et al.	
	A13	US-4,704,692	11-03-1987	Ladner	
	A14	US-4,816,567	03-28-1989	Cabilly et al.	
	A15	US-4,906,562	03-06-1990	Hellstrom et al.	
	A16	US-4,935,495	06-19-1990	Hellstrom et al.	
	A17	US-4,946,778	08-07-1990	Ladner et al.	
	A18	US-5,091,177	02-25-1992	Hellstrom et al.	
	A19	US-5,098,833	03-24-1992	Lasky et al.	
	A20	US-5,225,539	07-06-1993	Winter et al.	
	A21	US-5,260,203	11-09-1993	Ladner et al.	
	A22	US-5,434,131	07-18-1995	Linsley et al.	
	A23	US-5,455,030	10-03-1995	Ladner et al.	
	A24	US-5,500,362	03-19-1996	Robinson et al.	
	A25	US-5,521,288	05-28-1996	Linsley et al.	
	A26	US-5,530,101	06-25-1996	Queen et al.	
	A27	US-5,580,756	12-03-1996	Linsley et al.	
	A28	US-5,585,089	12-17-1996	Queen et al.	
	A29	US-5,597,707	01-28-1997	Marken et al.	
	A30	US-5,605,690	02-25-1997	Jacobs et al.	
	A31	US-5,637,481	06-10-1997	Ledbetter et al.	
	A32	US-5,645,835	07-08-1997	Fell, Jr. et al.	
	A33	US-5,677,425	10-14-1997	Bodmer et al.	
	A34	US-5,693,762	12-02-1997	Queen et al.	
	A35	US-5,709,859	01-20-1998	Aruffo et al.	
	A36	US-5,714,147	02-03-1998	Capon et al.	
	A37	US-5,736,137	04-07-1998	Anderson et al.	
	A38	US-5,770,197	06-23-1998	Linsley et al.	
	A39	US-5,773,253	06-30-1998	Linsley et al.	
	A40	US-5,776,456	07-07-1998	Anderson et al.	
	A41	US-5,795,572	08-18-1998	Diegel et al.	
	A42	US-5,807,734	09-15-1998	Diegel et al.	
	A43	US-5,844,093	12-01-1998	Kettleborough et al.	
	A44	US-5,844,095	12-01-1998	Linsley et al.	
	A45	US-5,869,049	02-09-1999	Noelle et al.	
	A46	US-5,869,620	02-09-1999	Whitlow et al.	
	A47	US-5,876,718	03-02-1999	Noelle et al.	
	A48	US-5,876,950	03-02-1999	Siadak et al.	
	A49	US-5,888,773	03-30-1999	Jost et al.	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 12-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/566,409-Conf. #3616
				Filing Date	August 24, 2006
				First Named Inventor	Jeffrey A. Ledbetter
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	2	of	7	Attorney Docket Number	31126/41458P3US

	A50	US-5,892,019	04-06-1999	Schlom et al.	
	A51	US-5,916,560	06-29-1999	Larsen et al.	
	A52	US-6,015,695	01-18-2000	Casterman et al.	
	A53	US-6,074,644	06-13-2000	Pastan et al.	
	A54	US-6,087,329	07-11-2000	Armitage et al.	
	A55	US-6,090,914	07-18-2000	Linsley et al.	
	A56	US-6,147,203	11-14-2000	Pastan et al.	
	A57	US-6,150,584	11-21-2000	Kucherlapati et al.	
	A58	US-6,194,551	02-27-2001	Idusogie et al.	
	A59	US-6,264,951	07-24-2001	Armitage et al.	
	A60	US-6,284,536	09-04-2001	Morrison et al.	
	A61	US-6,312,692	11-06-2001	Noelle et al.	
	A62	US-6,376,459	04-23-2002	Aruffo et al.	
	A63	US-6,384,198	05-07-2002	Diegel et al.	
	A64	US-6,410,319	06-25-2002	Raubitschek et al.	
	A65	US-6,444,792	09-03-2002	Gray et al.	
	A66	US-6,472,510	10-29-2002	Aruffo et al.	
	A67	US-6,482,919	11-19-2002	Ledbetter et al.	
	A68	US-6,623,940	09-23-2003	Ledbetter et al.	
	A69	US-6,641,809	11-04-2003	Linsley et al.	
	A70	US-6,815,540	11-09-2004	Pluckthun et al.	
	A71	US-7,074,403	07-11-2006	Goldenberg et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	B1	EP-0555880	08-18-1993	Bristol Myers Squibb Co. et al.		
	B2	EP-0586002	03-09-1994	Centro Immunologia Molecular		
	B3	EP-0682039	11-15-1995	Bristol Myers Squibb Co.		
	B4	EP-0757099	02-05-1997	Bristol Myers Squibb Co.		
	B5	EP-1186300	03-13-2002	Bristol Myers Squibb Co.		
	B6	WO-1989/07142	08-10-1989	Morrison et al.		
	B7	WO-1992/00092	01-09-1992	Bristol Myers Squibb Co.		
	B8	WO-1992/21755	12-10-1992	Genetech Inc.		
	B9	WO-1993/00431	01-07-1993	Bristol Myers Squibb Co.		
	B10	WO-1994/04678	03-03-1994	Casterman et al.		
	B11	WO-1994/05690	03-17-1994	Gross et al.		
	B12	WO-1994/25591	11-10-1994	Hamers et al.		
	B13	WO-1995/09917	04-01-1995	Coloma et al.		
	B14	WO-1996/34103	10-31-1996	Hamers et al.		
	B15	WO-1999/42077	08-26-1999	Xcyte Therapies Inc.		
	B16	WO-2000/44777	08-03-2000	ImClone Systems		

Examiner Signature		Date Considered	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 12-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/566,409-Conf. #3616
				Filing Date	August 24, 2006
				First Named Inventor	Jeffrey A. Ledbetter
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	3	of	7	Attorney Docket Number	31126/41458P3US

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	C1	AICHER et al., Characterization of human inducible costimulator ligand expression and function, J. Immunol., 164:4689-4696, 2000.	
	C2	ANDERSON et al., Targeted anti-cancer therapy using rituximab, a chimeric anti-CD-20 antibody (IDEC-c2B8) in the treatment of non-Hodgkin's B-cell lymphoma, Biochemical Society Transactions Colchester, Essex, Great Britain, pages 705-708, 1997.	
	C3	BATRA et al., Single-chain immunotoxins at the human transferrin receptor containing *Pseudomonas* exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv), Mol. Cell. Biol., 11:2200-2205, 1991.	
	C4	BEISKE et al., Triggering of neoplastic B cells via surface IgM and the cell surface antigens CD20 and CD40: responses differ from normal blood B cells and are restricted to certain morphologic subsets, Int. J. Cancer, 42:521-528, 1988.	
	C5	BREKKE et al., The structural requirements for complement activation by IgG: does it hinge on the hinge?, Immunol. Today, 16:85-90, 1995.	
	C6	BROWN et al., Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon, Blood, 73:651-661, 1989.	
	C7	BURGESS et al., Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue, J. Cell Biol., 111:2129-2138, 1990.	
	C8	BURKE et al., Radioimmunotherapy for acute leukemia, Cancer Control, 9:106-113, 2002.	
	C9	CAMPBELL et al., Biology, 5th edition, page 856, 1999.	
	C10	CARTER, Improving the efficacy of antibody-based cancer therapies, Nature, 1:118-129, 2001.	
	C11	CHAUDHARY et al., A recombinant immunotoxin consisting of two antibody variable domains, fused to *Pseudomonas* exotoxin, Nature, 339:394-397, 1989.	
	C12	CLARK et al., Activation of human B cells mediated through two distinct surface differentiation antigens, Bp35 and Bp50, PNAS USA, 83:4494-4498, 1986.	
	C13	CLARK et al., Structure, function, and genetics of human B cell-associated surface molecules, Adv. Cancer Res., 52:81-149, 1989.	
	C14	COLOMA, et al., The hinge as a spacer contributes to covalent assembly and is required for function of IgG, J. Immunol., 158:733-740, 1997.	
	C15	CRUSE et al., Illustrated Dictionary of Immunology, CRC Press, page 157, 1995.	
	C16	DAMLE et al., Direct helper T cell-induced B cell differentiation involves interaction between T cell antigen CD28 and B cell activation antigen B7, Eur. J. Immunol., 21:1277-1282, 1991.	
	C17	DAVIES et al., 'Camelising' human antibody fragments: NMR studies on VH domains , FEBS Letters, 339:285-290, 1994.	
	C18	DAVIS et at., High level expression in Chinese hamster ovary cells of soluble forms of CD4 T lymphocyte glycoprotein including glycosylation variants, J. Biol. Chem., 265:10410-10418, 1990.	
	C19	DESMYTER et al., Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme, Nat. Struct. Biol., 3:803-811, 1996.	
	C20	DIETSCH et al., Bispecific globulins, novel tools for the study of receptor cellular interactions, J. Immunol. Met., 162:123-132, 1993.	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 12-07 version)

Substitute for form 1449/PTO **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** *(Use as many sheets as necessary)*				***Complete if Known***	
				Application Number	10/566,409-Conf. #3616
				Filing Date	August 24, 2006
				First Named Inventor	Jeffrey A. Ledbetter
				Art Unit	1643
				Examiner Name	Not Yet Assigned
Sheet	4	of	7	Attorney Docket Number	31126/41458P3US

	C21	DIETSCH et al., Coengagement of CD2 with LEA-1 or VLA-4 by bispecific ligand fusion proteins primes T cells to respond more effectively to T cell receptor-dependent signals, J. Leukocyte Biol., 56:444-452, 1994.	
	C22	DILLMAN et al., Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma, J. Biol. Response Modifiers, 5:394-410, 1986.	
	C23	DORAI et al., Role of inter-heavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1, Mol. Immunol., 29:1487-1491, 1992.	
	C24	DUNCAN et al., The binding site for Clq on IgG, Nature, 322:738-740, 1988.	
	C25	DURIE et al., Prevention of collagen-induced arthritis with an antibody to gp39 the ligand for CD40 , Science, 261:1328-1330, 1993.	
	C26	EINFELD et al., Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, EMBO J., 7:711-717, 1988.	
	C27	FELL et al., Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2, J. Immunol., 146:2446-2452, 1991.	
	C28	FILPULA et al., Single-chain Fv designs for protein, cell and gene therapeutics, Exp. Opin. Ther. Patents, 9:231-245, 1999.	
	C29	FUNAKOSHI et al., Inhibition of human B-cell lymphoma growth by CD40 stimulation, Blood, 83:2787-2794, 1994.	
	C30	FUNAKOSHI et at., Differential *in vitro* and *in vivo* antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas, J. Immunother., 19:93-101, 1996.	
	C31	Genbank Accession No. L07414, Homo sapiens CD40 surface protein mRNA, complete cds, April 27, 1993.	
	C32	Genbank Accession No. M62541, Mouse CD20 cell surface protein mRNA, complete cds, July 26, 1993.	
	C33	Genbank Accession No. M62542, Mouse CD19 gene, complete cds, April 27, 1993.	
	C34	Genbank Accession No. M83312, Mouse CD40 mRNA, complete cds, September 23, 1996.	
	C35	Genbank Accession No. M84371, Human CD19 gene, complete cds, July 17, 1995.	
	C36	Genbank Accession No. X14046, Human mRNA for leukocyte antigen CD37, September 12, 1993.	
	C37	Genbank Accession No. X53517, R.norvegicus mRNA for antigen CD37, February 17, 1992.	
	C38	Genbank Accession No. X65453, M.musculus mRNA for CD40 ligand, April 26, 2001.	
	C39	Genbank Accession No. X67878, H.sapiens mRNA for CD40 ligand, June 6, 1997.	
	C40	Genbank Accession No. X96710, H.sapiens mRNA for CD40-ligand, February 13, 1997.	
	C41	Genbank Accession No. Y10507, H.sapiens mRNA for CD40 protein, September 4, 1997.	
	C42	GILLIES et al., Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities, Hum. Antibodies Hybridomas, 1:47-54, 1990.	
	C43	GILLILAND et al., Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments, Tissue Antigens, 47:1-20, 1996.	
	C44	HAMERS-CASTERMAN et al., Naturally occurring antibodies devoid of light chains, Nature, 363:446-448, 1993.	
	C45	HAYDEN et al., Antibody engineering, Curr. Opin. Immunol., 9:201-212, 1997.	
	C46	HAYDEN et al., Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen, Tissue Antigens, 48:242-254, 1996.	
	C47	HAYDEN et al., Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system, Ther. Immunol., 1:3-15, 1994.	
	C48	HEKMAN et al., Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody, Cancer Immunol. Immunother., 32:364 -372, 1991.	
	C49	HOLLENBAUGH et al., The human T cell antigen gp39, a member of the TNF gene family, is ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity, EMBO J., 11:4313-4321, 1992.	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 12-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/566,409-Conf. #3616
				Filing Date	August 24, 2006
				First Named Inventor	Jeffrey A. Ledbetter
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	5	of	7	Attorney Docket Number	31126/41458P3US

	C50	HOLLIGER et al., Engineered antibody fragments and the rise of single domains, Nat. Biotechnol., 23:1126-1136, 2005.	
	C51	HU et al., Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts, Cancer Res., 56:3055-3061 (abstract), 1996.	
	C52	HUDSON, Recombinant antibodies: a novel approach to cancer diagnosis and therapy, Exp. Opin. Invest. Drugs, 9:1231-1242, 2000.	
	C53	HUDSON, Recombinant antibody fragments, Curr. Opin. Biotechnol., 9:395-402, 1998.	
	C54	HUSTON et al., Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxigenin single-chain Fv analogue produced in *Escherichia coli*, PNAS USA, 85:5879-5883, 1988.	
	C55	ISENMAN, et al., Correlation between the exposure of aromatic chromophores, Biochemistry, 16:233-240, 1977.	
	C56	JOST et al., Mammalian expression and secretion of functional single chain Fv molecules, J. Biol. Chem., 269:26267-26273, 1994.	
	C57	KAMINSKI et al., Radioimmunotherapy of B-cell lymphoma with [131I] anti-B1 (anti-CD20) antibody, N. Eng. J. Med., 329:459-465, 1993.	
	C58	KATO et al., A conformational change in the Fc precludes the binding of two Fcγ receptor molecules to one IgG, Immunol. Today, 21:310-312, 2000.	
	C59	KLEIN et al., Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region, PNAS USA, 78:524-528, 1981.	
	C60	KOOLWIJK et al., Interaction between hybrid mouse monoclonal antibodies and the human high-affinity IgG FcR, huFcTRI, on U937, J. Immunol., 143:1656-1662, 1989.	
	C61	KORTT, et al., Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting, Biomol. Eng., 18:95-108, 2001.	
	C62	LAS VELD et al., Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19, Cancer Immunol. Immunother., 40:37-47, 1995.	
	C63	LAZAR et al., Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities, Mol. Cell. Biol., 8:1247-1252, 1988.	
	C64	LEDBETTER et al., Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40), J. Immunol., 138:788-794, 1987.	
	C65	LEE et at., Generation and characterization of a novel single-gene-encoded single-chain immunoglobulin molecule with antigen binding activity and effector functions, Mol. Immunol., 36:61-71, 1999.	
	C66	LI et al., Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification and effect on tumor growth, Cancer Immunol. Immunother., 49:243-252, 2000.	
	C67	LIN et al., Structure-function relationships in glucagon: properties of highly purified des-His-1-, monoiodo-, and (des-Asn-28, Thr-29)(homoserine lactone-27)-glucagon, Biochemistry, 14:1559-1563, 1975.	
	C68	LIU et at., Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity, J. Immunol., 139:3521-3526, 1987.	
	C69	MALONEY et al., IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, 90:2188-2195, 1997.	
	C70	MALONEY et al., IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma, J. Clin. Oncol., 15:3266-3274, 1997.	
	C71	MARTIN et al., Efficient neutralization and disruption of rhinovirus by chimeric ICAM-1 / immunoglobulin molecules, J. Virol., 67:3561-3568, 1993.	
	C72	MCLAUGHLIN et al., IDEC-C2B8 anti-CD20 antibody: final report on a phase III pivotal trial in patients (PTS) with relapsed low-grade or follicular lymphoma (LG/F NHL), Blood, 88:90a (abstract 349), 1996.	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 12-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/566,409-Conf. #3616
				Filing Date	August 24, 2006
				First Named Inventor	Jeffrey A. Ledbetter
				Art Unit	1643
(Use as many sheets as necessary)				Examiner Name	Not Yet Assigned
Sheet	6	of	7	Attorney Docket Number	31126/41458P3US

	C73	MICHAELSEN et al., Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region, Mol. Immunol., 29:319-326, 1992.	
	C74	MICHAELSEN et al., Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons, Scand. J. Immunol., 32:517-528, 1990.	
	C75	MICHAELSEN et al., One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge, PNAS USA 91:9243-9247, 1994	
	C76	MULTANI et al., Monoclonal antibody-based therapies for hematologic malignancies , J. Clin. Oncol., 16:3691-3710, 1998.	
	C77	MUÑOZ et al., The C(H)1 domain of IgG is not essential for C3 covalent binding: importance of the other constant domains as targets for C3, Int. Immunol., 10:97-106, 1998.	
	C78	MUYLDERMANS, Single domain camel antibodies: current status, J. Biotechnol., 74:277-302 (abstract), 2001.	
	C79	NIKULA et al., Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity, Mol. Immunol. 32:865-872, 1995.	
	C80	NUTTALL et al., Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagent, Curr. Pharm. Biotechnol., 1:253-263, 2000.	
	C81	PARK et al., Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens, Mol. Immunol., 37:1123-1130, 2000.	
	C82	PAUL, Fudamental Immunology, Raven Press, chapter 8, page 242, 1993.	
	C83	PAWSON et al., Treatment of T-cell prolymphocytic leukemia with human CD52 antibody, J. Clin. Oncol., 15:2667-2672, 1997.	
	C84	PRESS et al., Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Eng. J. Med., 329:1219-1224, 1993.	
	C85	PRESS et al., Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas, Blood, 69:584-591, 1987.	
	C86	Print-out of PubMed search for des-leucine (p. 1).	
	C87	RADAEV et al., Recognition of IgG by Fcγ receptor: the role of Fc glycosylation and the binding of peptide inhibitors, J. Biol. Chem., 276:16478-16483, 2001.	
	C88	RADAEV et al., The structure of a human type III Fcγ receptor in complex with Fc, J. Biol. Chem., 276:16469-16477, 2001.	
	C89	REDPATH et al., The influence of the hinge region length in binding of human IgG to human Fcγ receptors, Hum. Immunol., 59:720-727, 1998.	
	C90	ROUX et al., Comparisons of the ability of human IgG3 hinge mutants, IgM, IgE, and IgA2, to form small immune complexes: a role for flexibility and geometry, J. Immunol., 161:4083-4090, 1998.	
	C91	RUDIKOFF et al., Single amino acid substitution altering antigen-binding specificity, PNAS USA, 79:1979-1983, 1982.	
	C92	SCHEINBERG et al., A phase I toxicity, pharmacology, and dosimetry trial of monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma: effects of tumor burden and antigen expression, J. Clin. Oncol., 85:792-803, 1990.	
	C93	SCHWARTZ et al., A superactive insulin: [B10-aspartic acid]insulin(human), PNAS USA, 84:6408-6411, 1987.	
	C94	Search output from ATCC website for hybridomas: 2H7 (pp.1-2), 1 D8 (p.1) , HD37 (p. 1), G28-1 (p. 1), 4.4.220 (p. 1), Fc2-2 (p.1), UCHL-1 (p. 1), 5B9 (p. 1), L6 (p. 1), 10A8 (p. 1), 2e12 (p. 1), 40.2.36 (p. 1) and G19-4 (p. 1).	
	C95	SEGAL et al., Introduction: bispecific antibodies, J. Immunol. Met., 248:1-6, 2001.	
	C96	SENSEL et al., Engineering novel antibody molecules, Chem. Immunol., 65:129-158, 1997.	
	C97	SHAN et al., Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies, Blood, 91:1644-1652, 1998.	

Used in Lieu of PTO/SB/08A/B
(Based on PTO 12-07 version)

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/566,409-Conf. #3616
				Filing Date	August 24, 2006
				First Named Inventor	Jeffrey A. Ledbetter
(Use as many sheets as necessary)				Art Unit	1643
				Examiner Name	Not Yet Assigned
Sheet	7	of	7	Attorney Docket Number	31126/41458P3US

	C98	SHAN et al., Characterization of scFv-Ig constructs generated from the anti-CD20 mAb 1F5 using linker peptides of varying lengths, J. Immunol., 162:6589-6595, 1999.	
	C99	SHIN et al., Genetically-engineered antibodies: tools for the study of diverse properties of the antibody molecule, Immunol. Rev., 130:87-107, 1992.	
	C100	SHIN et al., Hybrid antibodies, Intern. Rev. Immunol., 10:177-186, 1993.	
	C101	SHU et al., Secretion of a single-gene-encoded immunoglobulin from myeloma cells, PNAS USA, 90:7995-7999, 1993.	
	C102	SMELLIE et al., Radioimmunotherapy of breast cancer xenografts with monoclonal antibody ICR12 against c-erbB2 p185: comparison of iodogen and N-succinimidyl 4-methyl-3-(tri-n-butylstannyl)benzoate radioiodination methods, Cancer Res. 55:5842S-5846S, 1995.	
	C103	SONDERMANN et al., The 3.2-A crystal structure of the human IgG1 Fc fragment-Fcγ RIII complex, Nature, 406:267-273, 2000.	
	C104	SOURIAU et al., Recombinant antibodies for cancer diagnosis and therapy, Exp. Opin. Biol. Ther., 3:305-318, 2003.	
	C105	SPORICI et al., ICOS ligand costimulation is required for T-cell encephalitogenicity, Clin. Immunol., 100:277-288, 2001.	
	C106	STEVENSON et al., Mechanisms in removal of tumor by antibody, Cell Biophys., 24:45-50, 1994.	
	C107	TAN, et al, Influence of the hinge region on complement activation, Clq binding, and segmental flexibility in chimeric human immunoglobulins, PNAS USA, 87:162-166, 1990.	
	C108	TAO, et al., Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region, J. Immunol., 143:2595-2601, 1989.	
	C109	THOMMESEN et al., Lysine 322 in the human IgG3 CH2 domain is crucial for antibody dependent complement activation, Mol. Immunol., 37:995-1004, 2000.	
	C110	TRAUNECKER et al., Bispecific single chain molecules (Janusins) target cytotoxic lymphocyte on HIV infected cells, EMBO J., 10:3655-3659, 1991.	
	C111	VAN DEN ABBEELE, et al., Antigen-binding site protection during radiolabeling leads to a higher immunoreactive fraction, J. Nucl. Med., 32:116-122, 1991.	
	C112	WALKER et al., Aglycosylation of human IgG1 and IgG3 monoclonal antibodies can eliminate recognition by human cells expressing Fcγ RI and/or Fcγ RII receptors, 1989, Biochem. J., 259:347-353, 1989.	
	C113	WARD et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*, Nature, 341:544-546 (abstract), 1989.	
	C114	WHITE et al., Activation of dense human tonsilar B cells: induction of c-myc gene expression via two distinct signal transduction pathways, J. Immunol., 146:846-53, 1991.	
	C115	WÖRN et al., Stability engineering of antibody single-chain Fv fragments, J. Mol. Biol., 305:989-1010, 2001.	
	C116	WU, et al., Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange, Protein Eng., 14:1025-1033, 2001.	
	C117	YE et al., Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB, Nat. Med., 8:343-348, 2002.	
	C118	YOKOTA et al Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms, Cancer Res., 52:3402-3408, 1992.	
	C119	ZHOROV, et al., Oxidative iodination of rabbit IgG: localization of the label in the Fc fragment and modification effects, Biokhimiia, 56:828-838, 1991.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.